The Medical Letter - 2022
Search or Select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
January 24, 2022 (Issue 1642)
- Paxlovid for Treatment of COVID-19
On December 22, 2021, the FDA issued an Emergency Use Authorization (EUA) for the investigational antiviral drug nirmatrelvir copackaged with the HIV-1 protease inhibitor ritonavir... - Molnupiravir for Treatment of COVID-19
The investigational oral antiviral drug molnupiravir (Merck/Ridgeback Biotherapeutics) was granted an FDA Emergency Use Authorization (EUA) on December 23, 2021 for treatment of mild to moderate... - In Brief: Mifepristone by Mail for Pregnancy Termination
The FDA has removed the requirement that mifepristone (Mifeprex, and generics), a progestin receptor antagonist approved for use in a regimen with the prostaglandin E1 analog misoprostol... - Ruxolitinib (Opzelura) for Atopic Dermatitis
The FDA has approved a 1.5% topical cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib (Opzelura – Incyte) for short-term, non-continuous chronic treatment of mild to... - Bupivacaine/Meloxicam (Zynrelef) for Postsurgical Pain
The FDA has approved a fixed-dose combination of the amide local anesthetic bupivacaine and the nonsteroidal anti-inflammatory drug (NSAID) meloxicam as an extended-release (ER)... - COVID-19 Updates
On January 3, the FDA amended its Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) to incorporate the following changes. The anti-SARS-CoV-2 antibody...
January 10, 2022 (Issue 1641)
- Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19
The FDA has issued an Emergency Use Authorization (EUA) for the investigational long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld – AstraZeneca) to be administered... - Antiviral Drugs for Influenza for 2021-2022
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at higher risk for complications (see Table... - In Brief: Twice-Yearly Paliperidone (Invega Hafyera) for Schizophrenia
Invega Hafyera (Janssen), a long-acting, extended-release (ER) formulation of the second-generation antipsychotic paliperidone palmitate, has been approved by the FDA for twice-yearly IM... - Comparison Chart: Antiviral Drugs for Influenza for 2021-2022 (online only)
View the Comparison Chart: Antiviral Drugs for Influenza for 2021-2022
